Previous 10 | Next 10 |
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently ...
2024-02-13 13:35:30 ET More on Merrimack Financial information for Merrimack Pharmaceuticals Read the full article on Seeking Alpha For further details see: Merrimack spikes as Ipsen wins FDA label expansion for cancer therapy
2023-12-17 17:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023. “During the third quarter we saw interest income on our cash and short term inve...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Merrimack Pharmaceuticals Inc. (MACK) is expected to report for Q1 2024
2023-09-19 12:25:41 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding f...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023. “We were excited to see the announcement from Ipsen that the U.S. Food and Drug Admi...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
2023-05-04 17:47:44 ET Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q1 GAAP EPS of $0.02. Merrimack reported a gain on the sale of assets for the first quarter ended March 31, 2023, of $139 thousand, attributable to an asset purchase option agreement on a pr...
News, Short Squeeze, Breakout and More Instantly...
Merrimack Pharmaceuticals Inc. Company Name:
MACK Stock Symbol:
NASDAQ Market:
Merrimack Pharmaceuticals Inc. Website:
2024-05-12 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidat...